Tevogen Bio Reports First Quarter 2024 Financial Results
29 mai 2024 08h00 HE
|
Tevogen Bio Inc
Tevogen Bio first quarter '24 financial results: Liability elimination of $94.9M. $11.3M of net income. Net cash operations $2.1M. $36M LOC.
Antion Biosciences announces development of safety-enhanced and off-the-shelf CAR T-cells for autoimmune disease
22 mai 2024 06h55 HE
|
ANTION BIOSCIENCES SA
Aiming for a best-in-class solution to treat and cure B-cell driven autoimmune diseases
[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
20 mai 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, May 20, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Colorectal Cancer Market Size, Trends and Insights By Type of Treatment (Surgery,...
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
16 mai 2024 14h00 HE
|
Tevogen Bio Inc
Former police chief & FBI National Academy graduate, William Keane, to work with functional leads, ensure policies, procure Tevogen’s lab space.
Immunology Collaboration and Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2016 - Company A-Z, Therapy Focus and Technology Type
16 mai 2024 10h45 HE
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
Uveitis Treatment Market and Competitive Landscape Report, 2024: Analysis of Growth Opportunities by Drug Class, Disease Type, Distribution Channel, and Region to 2030
16 mai 2024 07h11 HE
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Uveitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight - A USD 1.50 Billion+ Market Opportunity by 2030
14 mai 2024 08h50 HE
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering....
Immatics Announces First Quarter 2024 Financial Results and Business Update
14 mai 2024 07h00 HE
|
https://immatics.com/
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily...
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
13 mai 2024 16h47 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
08 mai 2024 11h00 HE
|
Siren Biotechnology, Inc.
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer